Marshall Wace, LLP Aeglea Bio Therapeutics, Inc. Transaction History

Marshall Wace, LLP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.5 - $2.66 $77,087 - $410,105	-154,175 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.87 - $4.77 $210,470 - $536,868	112,551 Added 270.4%	154,175 $355,000
Q4 2021 Feb 14, 2022	SELL	$3.5 - $8.42 $959,696 - $2.31 Million	-274,199 Reduced 86.82%	41,624 $197,000
Q3 2021 Nov 15, 2021	SELL	$6.03 - $7.95 $2.02 Million - $2.67 Million	-335,580 Reduced 51.52%	315,823 $2.51 Million
Q2 2021 Aug 13, 2021	SELL	$6.32 - $8.38 $3.41 Million - $4.52 Million	-539,836 Reduced 45.32%	651,403 $4.53 Million
Q1 2021 May 17, 2021	SELL	$6.76 - $8.57 $351,594 - $445,734	-52,011 Reduced 4.18%	1,191,239 $9.44 Million
Q4 2020 Feb 16, 2021	BUY	$7.02 - $9.83 $5,777 - $8,090	823 Added 0.07%	1,243,250 $9.78 Million
Q3 2020 Nov 16, 2020	SELL	$6.51 - $9.33 $42,236 - $60,533	-6,488 Reduced 0.52%	1,242,427 $8.81 Million
Q2 2020 Aug 13, 2020	BUY	$4.01 - $11.04 $1.64 Million - $4.52 Million	409,755 Added 48.83%	1,248,915 $11.6 Million
Q1 2020 May 15, 2020	BUY	$3.51 - $8.48 $20,193 - $48,785	5,753 Added 0.69%	839,160 $3.91 Million
Q4 2019 Feb 14, 2020	BUY	$7.23 - $8.55 $237,144 - $280,440	32,800 Added 4.1%	833,407 $6.37 Million
Q3 2019 Nov 14, 2019	BUY	$6.42 - $9.0 $911,055 - $1.28 Million	141,909 Added 21.54%	800,607 $6.16 Million
Q2 2019 Aug 14, 2019	BUY	$6.1 - $8.78 $1.73 Million - $2.48 Million	282,795 Added 75.23%	658,698 $4.51 Million
Q1 2019 May 14, 2019	BUY	$7.6 - $9.4 $2.86 Million - $3.53 Million	375,903 New	375,903 $3.03 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.